Exact Mass: 493.35320620000005
Exact Mass Matches: 493.35320620000005
Found 169 metabolites which its exact mass value is equals to given mass value 493.35320620000005,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Tiamulin
C28H47NO4S (493.32256220000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D06127 CONFIDENCE standard compound; INTERNAL_ID 1055
LysoPC(16:1(9Z)/0:0)
LysoPC(16:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(16:1(9Z)/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)/0:0), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
13-(3,4-Dimethyl-5-propylfuran-2-yl)tridecanoylcarnitine
C29H51NO5 (493.37670360000004)
13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO7 (493.30393680000003)
(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-(3,4-Dimethyl-5-pentylfuran-2-yl)undecanoylcarnitine
C29H51NO5 (493.37670360000004)
11-(3,4-Dimethyl-5-pentylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(3,4-dimethyl-5-pentylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(3,4-Dimethyl-5-pentylfuran-2-yl)undecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 11-(3,4-Dimethyl-5-pentylfuran-2-yl)undecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylthreonine
Chenodeoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylthreonine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylthreonine
Deoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylthreonine consists of the bile acid deoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
1-(9Z-Nonadecenoyl)-glycero-3-phosphoethanolamine
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
N(4)-Oleylcytosine arabinoside
[(2R,3S,4S,6R,7S,8R)-4-Ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[2-(diethylamino)ethylsulfanyl]acetate
C28H47NO4S (493.32256220000005)
Glycolipids
C24H50N2O6P+ (493.34063100000003)
Glycolipids is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Glycolipids can be found in chayote, chinese mustard, swamp cabbage, and winter squash, which makes glycolipids a potential biomarker for the consumption of these food products. Glycolipids are lipids with a carbohydrate attached by a glycosidic bond. Their role is to maintain the stability of the cell membrane and to facilitate cellular recognition, which is crucial to the immune response and in the connections that allow cells to connect to one another to form tissues. Glycolipids are found on the surface of all eukaryotic cell membranes, where they extend from the phospholipid bilayer into the extracellular environment .
Vinylamycin
C26H43N3O6 (493.31516980000004)
A 15-membered cyclodepsipeptide isolated from Streptomyces sp.M1982-63F1. It exhibits moderate activity against Gram-positive bacteria.
INDANOMYCIN
C31H43NO4 (493.31919180000006)
An indene that is (3aS,7aR)-2,3,3a,4,5,7a-hexahydro-1H-indene which is substituted at the 2-pro-R position by a 1H-pyrrol-2-ylcarbonyl group, at the 9-pro-S position by an ethyl group, and at the 5-pro-R position by a hexa-1,3-dineyl group in which position 4 has been substituted by a (2R,3S,6R)-6-[(1R)-1-carboxyethyl]-3-methyltetrahydropyran-2-yl group. It exhibits activity against Gram-positive bacteria as well as antihypertensive and antitumour. It also functions as an effective growth promoter for ruminants.
PC(16:1/0:0)
PC(16:1/0:0)[U]
PC(P-17:0/0:0)
C25H52NO6P (493.35320620000005)
LysoPC(16:1/0:0)
1-[(9E)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the 1-acyl group is (9E)-hexadecenoyl.
13-(3,4-Dimethyl-5-propylfuran-2-yl)tridecanoylcarnitine
C29H51NO5 (493.37670360000004)
11-(3,4-Dimethyl-5-pentylfuran-2-yl)undecanoylcarnitine
C29H51NO5 (493.37670360000004)
[2-[(E)-hexadec-9-enoyl]oxy-3-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO7 (493.30393680000003)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-nonadec-9-enoate
1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-[[(E)-octadec-9-enyl]amino]pyrimidin-2-one
[3-[(E)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
N-[(2S,3S,4R)-3,4-dihydroxy-15-methyl-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadecan-2-yl]formamide
C24H47NO9 (493.32506520000004)
[3-[(Z)-heptadec-9-enoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C25H52NO6P (493.35320620000005)
2-aminoethyl [2-hydroxy-3-[(Z)-icos-11-enoxy]propyl] hydrogen phosphate
C25H52NO6P (493.35320620000005)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
[2-propanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
3-Hydroxy-2-(2-hydroxytetradecanoylamino)undecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
3-Hydroxy-2-(2-hydroxypentadecanoylamino)decane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] butanoate
3-Hydroxy-2-(2-hydroxytridecanoylamino)dodecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
3-Hydroxy-2-(2-hydroxydodecanoylamino)tridecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] hexanoate
[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
[2-acetyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] propanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] pentanoate
2-aminoethyl [(2R)-2-hydroxy-3-[(E)-icos-1-enoxy]propyl] hydrogen phosphate
C25H52NO6P (493.35320620000005)
[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-acetamido-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(butanoylamino)-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(heptanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(decanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(hexanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
1-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A 1-O-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group is (9Z)-hexadecenoyl (palmitoleoyl).
2-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine(0:0/16:1) in which the 2-acyl group is specified as (9Z)-hexadecenoyl.
1-(1Z-heptadecenyl)-sn-glycero-3-phosphocholine
C25H52NO6P (493.35320620000005)
1-(1Z-eicosenyl)-glycero-3-phosphoethanolamine
C25H52NO6P (493.35320620000005)
[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the acyl group is specified as (9Z)-hexadecenoyl and is located at either position 1 or 2.
lysophosphatidylcholine 16:1
An lysophosphatidylcholine in which the acyl group is hexadecenoyl (position of double bond not specified). If R1 is hexadecenoyl and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is hexadecenoyl then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
lysophosphatidylcholine(0:0/16:1)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 16 carbons and 1 double bond.
Lysophosphatidylcholine(16:1/0:0)
A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 16 carbons and 1 double bond.
lysophosphatidylcholine (16:1/0:0)
A lysophosphatidylcholine 16:1 in which the acyl group is located at position 1.
LdMePE(18:1)
C25H52NO6P (493.35320620000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
5,8,13-trihydroxy-14-(1-hydroxy-4-methyldecan-3-yl)-3-isopropyl-6-methyl-11-methylidene-1-oxa-4,7,12-triazacyclotetradeca-4,7,9,12-tetraen-2-one
C26H43N3O6 (493.31516980000004)
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,4s,5r)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(1r,2s,3s,4s,5s,6r,8r,12r,13r,16r,19s,20s,21r)-14-ethyl-4,6,19,21-tetramethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane
C27H43NO7 (493.30393680000003)
(2-{[(2r)-3-[(9z)-hexadec-9-enoyloxy]-2-hydroxypropyl phosphonato]oxy}ethyl)trimethylazanium
(1r,2s,3s,4s,5s,6r,8r,9s,10s,13r,16s,17s,18s)-11-ethyl-8-hydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C27H43NO7 (493.30393680000003)
(3r,6s,9e)-5,8,13-trihydroxy-14-(2-hydroxyethyl)-3-isopropyl-6-methyl-11-methylidene-15-(octan-2-yl)-1-oxa-4,7,12-triazacyclopentadeca-4,7,9,12-tetraen-2-one
C26H43N3O6 (493.31516980000004)
(2e,4r,6r)-n-[(1's,3'r,4s,5s,5's,7'r)-6'-hydroxy-5-methoxy-6'-(2-oxopropyl)-4',8'-dioxaspiro[oxolane-2,2'-tricyclo[5.1.0.0³,⁵]octan]-4-yl]-4,6-dimethyldodec-2-enimidic acid
C27H43NO7 (493.30393680000003)
[4-(3,7-dimethylocta-1,6-dien-3-yl)-12-hydroxy-11-isopropyl-10-methyl-4,10,13-triazatricyclo[7.6.1.0⁵,¹⁶]hexadeca-1,5(16),6,8,12-pentaen-14-yl]methyl acetate
C30H43N3O3 (493.33042480000006)
(1s,2s,5s,6r,9r,12s,13r,16s,18s)-16-{[(2r,4s,5r,6r)-5-amino-4-methoxy-6-methyloxan-2-yl]oxy}-6,13-dimethyl-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosane-2,6-diol
(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23r,25r)-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosane-10,12,13,14,22,23-hexol
C27H43NO7 (493.30393680000003)
[(11s,14s)-4-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-12-hydroxy-11-isopropyl-10-methyl-4,10,13-triazatricyclo[7.6.1.0⁵,¹⁶]hexadeca-1,5(16),6,8,12-pentaen-14-yl]methyl acetate
C30H43N3O3 (493.33042480000006)
(2s,3r,4r,5s,6s)-6-{[(1s,2s,3s,4r,6r)-4,6-diamino-3-{[(2r,3s,6r)-3-amino-6-[(methylamino)methyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)-3-methyl-4-(methylamino)oxane-3,5-diol
6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosane-10,12,13,14,22,23-hexol
C27H43NO7 (493.30393680000003)
methyl (4z,8s,9e,11e)-2-hydroxy-4,8,12-trimethyl-15-[2-oxo-1-(2-phenylethyl)-5h-pyrrol-3-yl]pentadeca-4,9,11-trienoate
C31H43NO4 (493.31919180000006)
(1s,2s,6s,9s,10s,11r,12s,13s,14s,15s,18s,19s,22s,23s,25r)-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosane-10,12,13,14,22,23-hexol
C27H43NO7 (493.30393680000003)
11-ethyl-8-hydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
C27H43NO7 (493.30393680000003)
(2s)-2-[(2s,5r,6s)-6-[(3e,5e)-6-[(1r,3as,4r,5s,7ar)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(1r,2r)-2-[(2s,4e,6z,8r,9s,11r,13s,15s,16s)-7-(aminomethyl)-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
2-(6-{6-[1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl}-5-methyloxan-2-yl)propanoic acid
C31H43NO4 (493.31919180000006)
(2r,3r,6s,8r,12r,16s,20r,21s)-14-ethyl-4,6,19,21-tetramethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane
C27H43NO7 (493.30393680000003)
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,3ar,4s,5r,7as)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(1s,2s,6s,9s,10s,11r,12r,13s,15s,19s,22s,23s)-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosane-10,12,13,14,22,23-hexol
C27H43NO7 (493.30393680000003)
(3r,6s,9e)-5,8,13-trihydroxy-14-(1-hydroxy-4-methyldecan-3-yl)-3-isopropyl-6-methyl-11-methylidene-1-oxa-4,7,12-triazacyclotetradeca-4,7,9,12-tetraen-2-one
C26H43N3O6 (493.31516980000004)
(2r)-2-[(2r,5s,6r)-6-[(3e,5e)-6-[(1s,3as,4r,5r,7ar)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(3r,6r,9e,14s)-5,8,13-trihydroxy-14-[(3r,4s)-1-hydroxy-4-methyldecan-3-yl]-3-isopropyl-6-methyl-11-methylidene-1-oxa-4,7,12-triazacyclotetradeca-4,7,9,12-tetraen-2-one
C26H43N3O6 (493.31516980000004)
14-ethyl-4,6,19,21-tetramethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane
C27H43NO7 (493.30393680000003)